Goldman Sachs’s Achieve Life Sciences ACHV Stock Holding History

Goldman Sachs’s Portfolio ACHV Stock Details ACHV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-13	Closed	-$103K	–	7096
2014 Q2	$103K	Sell	13 -4	-24%	-$49.1K	﹤0.01%	6534
2014 Q1	$443K	Buy	+17	New	+$418K	﹤0.01%	5395

Other funds holding ACHV

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's ACHV Position: Q1 2026 in Review

Goldman Sachs reduced its Achieve Life Sciences (ACHV) stake by 66% in Q1 2026, selling an estimated $1.32M and leaving 152,952 shares worth $450K. The position accounts for ﹤0.01% of the portfolio, ranked #5662.

Goldman Sachs first reported a position in ACHV in Q1 2014 and has held it in 25 quarters since. The position peaked at $2.24M in Q4 2025. 81 funds tracked by Wall St. Rank hold ACHV as of Q1 2026.

Goldman Sachs held 152,952 shares of Achieve Life Sciences worth $450K as of Q1 2026.
Goldman Sachs sold 297,976 Achieve Life Sciences shares in Q1 2026, an estimated $1.32M.
Achieve Life Sciences made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5662 holding.
Goldman Sachs first reported a position in Achieve Life Sciences in Q1 2014 and has held it in 25 quarters since.
Goldman Sachs's Achieve Life Sciences position peaked at $2.24M in Q4 2025.
81 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.